Fibre-optic probe to fight cancer:
This article was originally published in Clinica
Executive Summary
UK researchers have developed a fibre-optic probe which tells doctors which cancers can be treated with radiotherapy and which will resist. The £17,000 ($27,000) device, called Oxylite, measures the amount of oxygen in a tumour - the more oxygen present, the easier it is to kill the tumour with radiotherapy. The researchers, from the Cancer Research Campaign Advanced Technology Group in London, said the device has wider applications in plastic surgery, head injuries, shock and heart treatments.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.